GoodRx has formed a partnership with drug data giant Surescripts, which will allow healthcare providers to access information on the cash prices of drugs.
Surescripts, based in Arlington, Virginia, dominates the e-prescription market, providing the technology to send clinicians’ e-prescriptions directly to pharmacies. It is owned by CVS Health and Express Scripts, and delivered nearly 2 billion prescriptions through its software last year.
It also sells a service that allows prescribing clinicians to view drug prices specific to patient insurance coverage and complete pre-authorization as needed.
Although Surescripts can share information on the prices of drugs covered by insurance, as well as retail and mail order options, the partnership will add GoodRx’s cash payment price to the service.
Justin Fengler, GoodRx’s senior vice president of strategy and business development, said: “Independently, GoodRx has established relationships with other EHRs we have built in, such as Allscripts. This expands the scope of influence.”
This integration is particularly helpful in offsetting situations where providers may not have health plan drug pricing information or patients do not have health insurance.
“It’s impossible to ignore the affordability or coverage of drugs,” Feng Le said in an interview with Zoom.
GoodRx provides cash payment discounts for drugs. The Santa Monica-based startup went public last year and raised more than $1 billion through an IPO.
This service is usually used by patients without medical insurance or high deductible plans, but may also be useful in the following puzzling situations Insured medicines are more expensive Than cash payment.
Other competitors, such as Amazon, are building their own drug price comparison tools. After acquiring PillPack, Amazon launched its own pharmacy service last year, but it still focuses on prescription drug delivery.
PillPack used Surescripts’ drug data through a third-party company called ReMy Health. However, tensions between the two companies increased. In the year after the acquisition, Surescripts Ban ReMy Health as a supplier, Because Amazon threatened to file a lawsuit.
Photo credit: Stas_V, Getty Images
